Educational guide · not FDA-approved

A guide to Cagrilintide — regulatory status and buying considerations

Cagrilintide is not FDA-approved for human use. This page explains the regulatory status, what to know before considering purchase, and how to evaluate any vendor if you choose to source it. We do not maintain a verified vendor directory for research peptides.

FDA status
Investigational. Not FDA-approved as mon
2026 status
Cagrilintide as monotherapy is research-only in 20…
Typical dose
0.25-2.4 mg (once weekly)
Half-life
~7-8 days (159-195 hours)

Cagrilintide is a long-acting amylin analog; binds amylin receptors amy1 and amy3 in the area postrema and hindbrain to suppress appetite and slow gastric emptying. designed to pair with glp-1 receptor agonists like semaglutide for additive weight-loss effect. that has not been approved by the FDA for any medical use in the United States. Cagrilintide as monotherapy is research-only in 2026. CagriSema (cagrilintide + semaglutide) under FDA review; Novo Nordisk filed NDA December 2025 for once-weekly weight-management indication. Not yet available through standard pharmacy channels. It is sold by some third-party suppliers as a research chemical labeled "for research purposes only" and "not for human consumption."

The Peptide Toolkit covers Cagrilintide editorially — including its mechanism of action, dosing protocols used in research, and current regulatory status — for informational purposes only. We do not endorse off-label human use, and we do not maintain a verified vendor list for research-grade peptides. This page exists to help you understand the regulatory and quality landscape, not to direct you toward a specific seller.

Why we don’t list specific vendors for Cagrilintide

Editorial integrity comes first. Research peptides occupy a regulatory gray area: legal to sell as chemicals, not legal to market for human use. Affiliating with vendors in this space — even reputable ones — can be interpreted as endorsing personal use of an unapproved drug.

We don’t think that aligns with our mission. The Peptide Toolkit is built to educate, support legitimate medical use, and provide free tools (the dosing calculator, dosing guides) for people working with their healthcare providers. Routing research peptide buyer traffic to specific vendors doesn’t fit that mission.

We may revisit this in the future if the regulatory status of research peptides clarifies or if specific vendors achieve compounding eligibility through licensed pharmacies. Until then, we focus on what we can verify and stand behind.

If you choose to source Cagrilintide anyway: how to evaluate a vendor

We can’t recommend specific vendors, but we can share what to look for. If you’ve decided to proceed with sourcing a research peptide, these are the criteria that separate higher-quality suppliers from lower-quality ones:

  • Published third-party Certificate of Analysis (COA). Real third-party labs (not the vendor’s own). HPLC + mass spectrometry results showing >98% purity. Self-issued COAs don’t count.
  • Identity verification via mass spectrometry. Confirms the molecule is actually what’s labeled.
  • US-based shipping (for US buyers). Customs seizure risk on international shipments. Domestic shipping is more reliable.
  • Established business operations. A real address, real customer service contact, real refund/return policy. Pop-up sites with anonymous owners are red flags.
  • Reasonable storage and handling claims. Lyophilized peptides require cold storage prior to shipping. Vendors that don’t address this raise concerns.
  • No human-use marketing claims. Legitimate research peptide vendors label products "for research only" and don’t make medical claims. Vendors that explicitly market for human use are operating outside the legal framework that allows research peptide sales at all.
  • Realistic pricing. Research-grade Cagrilintide typically costs in a defined range. Significantly cheaper products often signal substitution, dilution, or counterfeit. Significantly more expensive products may be premium quality or may simply be overpriced.

Things to know before considering Cagrilintide

  • Not FDA-approved for any medical use. No FDA-approved labeling means no standardized dosing, no quality assurance, no consumer protection if something goes wrong.
  • The regulatory environment is evolving. Cagrilintide as monotherapy is research-only in 2026. CagriSema (cagrilintide + semaglutide) under FDA review; Novo Nordisk filed NDA December 2025 for once-weekly weight-management indication. Not yet available through standard pharmacy channels. Personal possession and use exist in a legal gray area that could change with little notice.
  • Counterfeit and substituted products exist. Without FDA-approved supply chains, product authenticity depends entirely on the vendor’s testing practices. Third-party COAs are the only verification.
  • No medical oversight. Without a prescribing physician, you have no professional guidance on dosing, interactions, contraindications, or what to do if you experience adverse effects.
  • Discuss with a licensed healthcare professional. Even if you choose to proceed independently, having a doctor who knows what you’re using improves safety significantly.

What we recommend instead

If your interest in Cagrilintide is driven by a specific health goal, there are usually legitimate, FDA-approved alternatives that achieve similar outcomes through prescription pathways:

  • Talk to a longevity-focused or integrative medicine physician. Many will work with patients on peptide protocols using legally compounded products through licensed 503A pharmacies (where eligible).
  • Explore FDA-approved alternatives. For specific health goals, FDA-approved medications often exist that achieve similar outcomes with established safety profiles.
  • Read our Cagrilintide dosing guide for educational context on what the research literature actually says — not what marketing pages claim.
  • Use our free dose calculator if you’re working with a prescriber on a legitimate compounded protocol.

Authoritative sources

Information on this page is sourced from primary regulatory and peer-reviewed publications, not vendor marketing materials. Citations below for further reading:

Stay informed

The regulatory status of research peptides changes frequently. We update this page when FDA actions, scheduling changes, or compounding eligibility shifts. Subscribe to our newsletter for quarterly updates on peptide regulation and dosing research.

[Newsletter signup form — replace with

Get peptide updates

Monthly peptide updates and FDA alerts. No spam, unsubscribe anytime.



init error', e); } catch(_){} } } })();
shortcode in production]

Editorial commitment

We list vendors only when we can verify their licensing, testing, and FDA standing. We do not maintain affiliate relationships with research peptide suppliers. Our editorial decisions are independent of commercial relationships.

Disclaimer: The Peptide Toolkit provides educational information only and is not a medical provider or pharmacy. We do not endorse off-label use of research peptides. Anyone considering use of an unapproved drug should consult a licensed healthcare professional. This page contains no affiliate links to research peptide vendors. Last data review: May 11, 2026.